Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
What's New in Pemphigus Management
Description
Professor Katarina Patsatzi presented new developments in the management of pemphigus, a challenging autoimmune blistering disease characterized by painful skin lesions and a significant impact on patients' quality of life. Traditional treatment primarily involved steroids, which often led to delays in diagnosis, multiple relapses, and various comorbidities. Recent advancements include the approval of rituximab, a CD20 monoclonal antibody, as a first-line therapy for pemphigus vulgaris, showing promising results with reduced relapse rates. The presentation highlighted the importance of integrating mental health support due to the high incidence of psychiatric disorders in these patients. Future therapies include second and third-generation monoclonal antibodies, BTK inhibition, and potential interventions targeting specific disease mechanisms like FCRN inhibition and the blockade of the fast ligand. These emerging treatments aim to enhance efficacy, improve disease control, reduce side effects, and ultimately elevate patients' quality of life. The ongoing quest is for novel solutions that minimize reliance on conventional steroids and achieve durable remissions with improved safety.
View moreConclusions
- Pemphigus management faces difficulties including delayed diagnosis, chronicity, and high psychosocial burdens.
- Immunotherapy, notably rituximab, is now the primary treatment for pemphigus vulgaris.
- Rituximab has revolutionized treatment but may have severe side effects, and about 10% of patients do not respond adequately.
- Predictive factors for early relapse can help tailor treatment, with additional rituximab infusions significantly reducing relapse rates.
- Emerging therapies include BTK inhibitors like rilzabrutinib, which show promise in achieving rapid disease control.
- Subcutaneous administration of ofatumumab shows faster disease control and higher remission rates compared to conventional therapies.
- Continued research into new treatments and optimized use of existing medications is necessary to improve patient outcomes.
- Integrating mental health support is crucial for improving the quality of life in pemphigus patients.
- Aikaterini Patsatsi, MD, MSc, PhD. Professor of Dermatology, Center of Expertise on AIBD - Papageorgiou General Hospital, 2nd Dermatology Department, Aristotle University School of Medicine, Thessaloniki, GREECE.
- Psychosocial burden of autoimmune blistering diseases: A comprehensive survey study. J Eur Acad Dermatol Venereol. 2025;39:350-356. White MA, Hoffman VM, Yale M, Strong R, Tomayko MM.
- Immunotherapy for Pemphigus: Present and Future. Frontiers in Medicine. published: 15 June 2022. doi: 10.3389/fmed.2022.901239.
- IMPROVED 2ND - EADV guidelines 2020. Guidelines on the management of pemphigus vulgaris and foliaceus.
- REVIEW 1. Didona D, Maglie R, Eming R and Hertl M (2019) Pemphigus: Current and Future Therapeutic Strategies. Front. Immunol. 10:1418. doi: 10.3389/fimmu.2019.01418.
- Key Points. Optimizing Pemphigus Management With Rituximab. JAMA Dermatology Published online February 5, 2025.
- Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study. Journal of Investigative Dermatology. (2024) 144, 1762-1771; doi:10.1016/j.jid.2024.03.014.
- Bruton Tyrosine Kinase Inhibition in Pemphigus: An Embattled Frontier. Journal of Investigative Dermatology. (2024) 144, 1667-1670; doi:10.1016/j.jid.2024.03.014.
- Blocking soluble Fas Ligand ameliorates pemphigus: PC111. Frontiers in Immunology. 14:1193032. doi: 10.3389/fimmu.2023.1193032.